Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Marcel Reiser"'
Autor:
Carsten, Zwick, Josef, Birkmann, Norma, Peter, Heinrich, Bodenstein, Roland, Fuchs, Mathias, Hänel, Marcel, Reiser, Manfred, Hensel, Michael, Clemens, Samira, Zeynalova, Marita, Ziepert, Michael, Pfreundschuh, Frank, Tympner
Publikováno v:
Annals of Hematology. 87:717-726
To compare toxicity of etoposide bolus with continuous infusion and to assess the efficacy of the CEMP (cisplatinum, etoposide, mitoxantrone, prednisone) regimen, 47 patients with refractory or relapsed aggressive non-Hodgkin's lymphoma older than 60
Publikováno v:
Seminars in Hematology. 43:221-229
The introduction of the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen 30 years ago was the great breakthrough in the treatment of advanced-stage aggressive lymphomas. About 50% of all patients treated with CHOP achieved co
Publikováno v:
Leukemia & Lymphoma. 46:1729-1734
The aim of the present study was to evaluate the feasibility and efficacy of the intensified induction chemotherapy regimen ACOMED for patients with aggressive non-Hodgkin's lymphoma (NHL). Untreated adult patients with aggressive NHL, presenting wit
Autor:
Bernd Dörken, Andreas Engert, Marcel Reiser, Markus Y. Mapara, M. Sieber, Volker Diehl, Hartmut Kirchner, Dieter K. Hossfeld, Christian Rudolph, Andreas Josting
Publikováno v:
Annals of Oncology. 13:1628-1635
An important variable affecting outcome in relapsed and refractory Hodgkin's disease (HD) is the potential of conventional salvage chemotherapy to reduce tumor volume before high-dose chemotherapy (HDCT) and autologous stem cell transplantation. Curr
Autor:
Juergen Wolf, Marcel Reiser, U. Rueffer, Hans Tesch, PD Wickramanayake, Andreas Josting, Diehl, D. Söhngen, Andreas Engert, Andreas Draube
Publikováno v:
Leukemia & Lymphoma. 37:115-123
We performed a phase II study to determine the efficacy of maximal cytoreductive therapy with up to five cycles of Dexa-BEAM (dexamethasone, carmustine [BCNU], etoposide, cytarabine, and melphalan) followed by high-dose chemotherapy (HDCT) and autolo
Autor:
Christoph Scheid, Andreas Draube, D. Söhngen, Hans Tesch, Markus Y. Mapara, Volker Diehl, Marcel Reiser, J. Wolf, Andreas Josting, J. Chemnitz, Andreas Engert
Publikováno v:
Bone Marrow Transplantation. 23:1223-1228
High-dose chemotherapy (HDCT) followed by autologous blood stem cell transplantation is considered the treatment of choice for patients with relapsed or resistant aggressive non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD). However, several aut
Autor:
S. Bamborschke, R. Lehrke, R. Schröder, B. Salzberger, Hans Tesch, Volker Diehl, Marcel Reiser, Gerd Fätkenheuer, Daniel Re
Publikováno v:
Journal of Infection. 38:26-29
Two cases of opportunistic cerebral infections in HIV-negative cancer patients due to chemotherapy induced immunosuppression are reported. A 61-year-old patient with low grade lymphoma (immunocytoma as referred to the Kiel classification) developed s
Autor:
Martin Wilhelm, B. Dederichs, M. Engelhard, Roland Schnell, M. E. Scheulen, S. Baltes-Engler, Hans Tesch, Volker Diehl, Bernhard Wörmann, F. Kupper, B. Lathan, B. Winterhalter, Marcel Reiser, Andreas Engert
Publikováno v:
Leukemia & Lymphoma. 24:513-522
We report a phase-II study of idarubicin, ifosphamide and etoposide (IIVP-16) in heavily pretreated patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. The IIVP-16 regimen consisted of idarubicin (10 mg/m2 i.v. days 1 + 2 or days
Autor:
Andreas Engert, Marcel Reiser, Annika Juergens, Gabriele Schackert, Uwe Schlegel, Frank Kroschinsky, Marlies Vogt-Schaden, Klaus Fliessbach, Ingo G.H. Schmidt-Wolf, Martina Deckert, Rolf Fimmers, Michael Linnebank, Heinz Reichmann, Gerlinde Egerer, Sabine Rogowski, Udo Bode, Hendrik Pels, Volker Diehl, Axel Glasmacher, Ulrich Herrlinger
Objective To evaluate long-term progression-free survival and overall survival, quality of life, and cognitive function in primary central nervous system lymphoma after systemic and intraventricular chemotherapy without radiotherapy. Methods A long-t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1d4ce93e44602c3a11011ca32f39e88
https://www.zora.uzh.ch/id/eprint/34873/
https://www.zora.uzh.ch/id/eprint/34873/
Publikováno v:
European Journal of Clinical Microbiology & Infectious Diseases. 17:58-60
Raynaud's phenomenon is a common vascular side effect of chemotherapy drug regimens. Chemotherapy-induced Raynaud's phenomenon leading to acral gangrene has rarely been reported. In this report, one patient who developed gangrene after bleomycin and